Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets

AVENUE THERAPEUTICS, INC.

Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.
Delisting due to failure to maintain minimum $2.5M stockholders' equity per Nasdaq Rule 5550(b)(1).
Company failed to meet conditions of Panel exception requiring disclosure of equity-increasing transactions by March 14.
Common stock (ATXI) expected to begin trading on OTC Markets on March 19, 2025.
Company will continue filing periodic reports with SEC but warns of uncertain trading liquidity.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-024505
form_type: 8-K
ticker: ATXI
cik: 0001644963
company_name: AVENUE THERAPEUTICS, INC.
filed_at: 2025-03-17T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.289108+00:00
generated_at: 2026-05-24T15:44:27.898183+00:00
sec_items: ["3.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-024505
json_url: https://secwatch.observer/filing/0001104659-25-024505.json
markdown_url: https://secwatch.observer/filing/0001104659-25-024505.md
text_url: https://secwatch.observer/filing/0001104659-25-024505.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465925024505/0001104659-25-024505-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465925024505/tm259546d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-024505

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.